Isomaltulose (Palatinose®): a review of biological and toxicological studies

BAR Lina, D Jonker, G Kozianowski - Food and Chemical Toxicology, 2002 - Elsevier
Isomaltulose is a natural occurring disaccharide composed of α-1,6-linked glucose and
fructose. Commercial isomaltulose is produced from sucrose by enzymatic rearrangement and …

[HTML][HTML] The prevalence of mental health problems in sub-Saharan adolescents: A systematic review

…, AK Napp, AS Dessauvagie, DJ Stein, D Jonker… - Plos one, 2021 - journals.plos.org
Background and purpose Most research regarding child and adolescent mental health
prevention and promotion in low-and middle-income countries is undertaken in high-income …

[HTML][HTML] K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

…, DJ Jonker, CJ O'Callaghan, D Tu… - … England Journal of …, 2008 - Mass Medical Soc
Background Treatment with cetuximab, a monoclonal antibody directed against the epidermal
growth factor receptor, improves overall and progression-free survival and preserves the …

Adjuvant chemotherapy for stage II and III colon cancer following complete resection: a cancer care Ontario systematic review

BM Meyers, R Cosby, F Quereshy, D Jonker - Clinical oncology, 2017 - Elsevier
The objective of this systematic review was to provide current evidence regarding the use of
adjuvant systemic chemotherapy for stage II and III colon cancer following curative intent …

[HTML][HTML] Cetuximab for the treatment of colorectal cancer

DJ Jonker, CJ O'Callaghan, CS Karapetis… - … England Journal of …, 2007 - Mass Medical Soc
Background Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth
factor receptor (EGFR), has activity against colorectal cancers that express EGFR. Methods …

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label …

…, D Jonker, S Osborne, N Andre, D Waterkamp… - The lancet …, 2013 - thelancet.com
Background Elderly patients are often under-represented in clinical trials of metastatic colorectal
cancer. We aimed to assess the efficacy and safety of bevacizumab plus capecitabine …

Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

…, DJ Jonker, F Di Nicolantonio, A Sartore-Bianchi, D Tu… - Jama, 2010 - jamanetwork.com
… Because the glycine (G)-to-aspartate (D) transition mutation is the most frequent codon
13 mutation in colorectal cancer, 5 we studied the association of this p.G13D mutation with …

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

CJ Breitbach, J Burke, D Jonker, J Stephenson… - Nature, 2011 - nature.com
The efficacy and safety of biological molecules in cancer therapy, such as peptides and small
interfering RNAs (siRNAs), could be markedly increased if high concentrations could be …

Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies

RM Savic, DM Jonker, T Kerbusch… - … of pharmacokinetics and …, 2007 - Springer
Purpose: To compare the performance of the standard lag time model (LAG model) with the
performance of an analytical solution of the transit compartment model (TRANSIT model) in …

[HTML][HTML] Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO. 17

SY Brulé, DJ Jonker, CS Karapetis… - European journal of …, 2015 - Elsevier
… (a–d) Kaplan–Meier curves showing the relationship between the primary site of tumour (right-
(RC) versus left-… (D) Comparing PFS in all LC patients receiving cetuximab versus BSC. …